BioCentury
ARTICLE | Product Development

Translate Bio brings chronic disease-scale manufacturing to COVID-19 mRNA vaccine

Chronic disease focus teed up company’s capacity to make hundreds of millions of doses of mRNA vaccine

May 21, 2020 4:38 AM UTC

Translate Bio and Sanofi’s bid to develop a COVID-19 mRNA vaccine highlights how manufacturing capacity is among the most visible differentiating factors at this stage in the pandemic counter-response.

The partners’ program is one of at least nine preclinical mRNA vaccines in development for COVID-19, behind clinical candidates from Moderna Inc. (NASDAQ:MRNA) and BioNTech SE (NASDAQ:BNTX) (see “COVID-19 Therapies and Vaccines: Clinical and Preclinical”). ...

BCIQ Company Profiles

Sanofi

Translate Bio Inc.